AntriaBio to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Live Webcast of AntriaBio's Presentation on February 11, 2014 at 2:30 p.m. ET
MENLO PARK, CA -- (Marketwired) -- 02/05/14 -- AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that the Company will be presenting at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.
Nevan Elam, Chairman and Chief Executive Officer, will present the Company's 2014 corporate business outlook, including plans and milestones for the development of the Company's lead diabetes product candidate, AB101, a once-a-week injectable basal insulin.
Mr. Elam stated, "I look forward to sharing an update on AntriaBio's strategic priorities for 2014 and our plans to advance AB101 into clinical studies. The Company has a robust development strategy outlined for our proprietary, microsphere formulation of insulin that has the potential to be administered once per week and transform the treatment paradigm of the basal insulin market."
A live audio webcast of the presentation will be available in the Investor Relations section in the IR Calendar on the AntriaBio website at www.antriabio.com. The webcast presentation will be archived on the Company's website for 90 days following the event.
About BIO CEO & Investor Conference
The 16th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2013 CEO & Investor Conference featured 1,380 partnering meetings, 148 company presentations, and 1,400 attendees, over half of which were investors.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
For more information visit: www.antriabio.com.
This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.
AntriaBio, Inc. Contact:
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Source: AntriaBio Inc.
Released February 5, 2014